95 results
8-K
EX-1.1
STRO
Sutro Biopharma Inc
2 Apr 24
Entry into a Material Definitive Agreement
5:10pm
and protection of health and safety or the environment which are applicable to its business (“Environmental Laws”). There has been no storage, generation … Health and Safety Act) relating to the protection of human health and safety in the workplace (“Occupational Laws”); (B) has received all material
424B5
STRO
Sutro Biopharma Inc
2 Apr 24
Prospectus supplement for primary offering
4:58pm
on ovarian and endometrial cancers. The Phase 1 trial assessing safety, tolerability and preliminary efficacy of luvelta to treat platinum resistant ovarian … cancer has been completed. In January 2024, we reported near-final results from this Phase 1 trial, in which luvelta exhibited a manageable safety
8-K
EX-99.1
STRO
Sutro Biopharma Inc
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
) target
»STRO-003 has shown robust monotherapy efficacy and potential for a differentiated safety profile in preclinical development in solid tumors
8-K
EX-1.1
1rbuay
9 Feb 24
Other Events
4:27pm
424B5
ohidkh qyc8k
9 Feb 24
Prospectus supplement for primary offering
4:25pm
8-K
jwesn7ymnzzn ch
8 Jan 24
Results of Operations and Financial Condition
7:31am
8-K
EX-99.1
858n rhjxo1
8 Jan 24
Results of Operations and Financial Condition
7:31am
8-K
EX-99.1
w1bszpm5t9wnyuhre
13 Nov 23
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
8-K
EX-99.1
cr76nd2yn4oldmt22or
10 Aug 23
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:31pm
8-K
EX-99.1
n4ath9b
15 May 23
Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
8:01am
8-K
EX-99.1
rsj 2k3bh
30 Mar 23
Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
4:32pm